Legal & General Group Plc Raises Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Legal & General Group Plc raised its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 26.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 253,426 shares of the company's stock after buying an additional 53,458 shares during the period. Legal & General Group Plc owned about 0.06% of Recursion Pharmaceuticals worth $1,713,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after buying an additional 9,737,196 shares during the period. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $23,429,000. Geode Capital Management LLC increased its holdings in Recursion Pharmaceuticals by 12.1% during the 4th quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock valued at $41,160,000 after purchasing an additional 655,238 shares during the period. Institute for Wealth Management LLC. bought a new position in Recursion Pharmaceuticals during the 4th quarter valued at approximately $3,928,000. Finally, Platinum Investment Management Ltd. lifted its holdings in Recursion Pharmaceuticals by 293.9% in the 4th quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company's stock worth $4,955,000 after buying an additional 546,929 shares during the period. 89.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Morgan Stanley cut their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $8.20.

Recursion Pharmaceuticals Price Performance

RXRX stock opened at $5.73 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a 50 day moving average price of $6.21 and a 200-day moving average price of $6.77. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -3.75 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to analysts' expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's quarterly revenue was down 57.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.42) EPS. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.